Table 2 Cumulative incidence of toxicities
| Â | Toxicity grade | |||
|---|---|---|---|---|
| Â | Sorafenib as First Line Treatment (N = 59) | Sorafenib as Second Line Treatment (N = 39) | ||
Toxicity | 1–2 | 3–4 | 1–2 | 3–4 |
Hand-foot syndrome | 44 | 8 | 21 | 5 |
Alopecia | 41 | 1 | 25 | 0 |
Rash | 22 | 0 | 11 | 0 |
Mucositis (oral cavity) | 11 | 1 | 5 | 0 |
Diarrhea | 25 | 1 | 16 | 0 |
Hypertension | 14 | 1 | 7 | 1 |
Fatigue & Anepithymia | 41 | 1 | 30 | 2 |
Weight loss | 6 | 0 | 3 | 0 |
Hemorrhage (nasal | Â | Â | Â | Â |
mucocutaneous) | 6 | 0 | 3 | 0 |
Anemia | 7 | 1 | 5 | 0 |
Thrombocytopenia | 0 | 0 | 1 | 0 |
Leukopenia | 0 | 0 | 0 | 0 |
Hemorrhage (digestive tract) | 0 | 1 | 1 | 2 |
Hematuria | 4 | 0 | 0 | 0 |
Hemoptysis | 8 | 1 | 4 | 1 |
Liver dysfunction | 7 | 2 | 3 | 0 |
Angina | 0 | 1 | 0 | 0 |